Different aspects of adherence to antihypertensive treatments

References

• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC VII report. JAIVIA 289, 2560–2572, (2003).
   PubMed Web of Science ®Google Scholar
• •Highlights prevention, detection, evaluation and treatment of high blood pressure.
   Google Scholar
• European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension.' Hypertens. 21,1011–1053 (2003).
   Google Scholar
• Cramer J. Consequences of intermittent treatment for hypertension: the case of medication compliance and persistence. Am. jMm. Cate 4(11), 1563–1568 (1998).
   Google Scholar
• ••Provides a review of the literature about patient behavior towards antihypertensive treatments.
   Google Scholar
• Berto P, Lopatriello S. Long-term social costs of hypertension. Expert Rev Pharmacoeconomics Outcomes Res. 3(1), 33–40 (2003).
   Google Scholar
• •Useful for the social economic burden of noncompliacne in antihypertensive treatment.
   Google Scholar
• Paramore LC, Halpern MT, Lapuerta P et al Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am. J. Manag. Care 7(4), 389–398 (2001).
   Google Scholar
• Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JR Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med. Care 35(11), 1164–1170 (1997).
   PubMed Web of Science ®Google Scholar
• Mallion JM, Baguet JP, Siche JP et al Compliance, electronic monitoring and antihypertensive drugs. J. Hypertens. 16\(Suppl. 1), S75—S80 (1997).
   Google Scholar
• Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press. Mon. 5 (Suppl. 1), S31—S34 (2000).
   Google Scholar
• Cramer J. Medicine partnership. Heart 89(Suppl. II), 1119–1121 (2003).
   Google Scholar
• ••Useful for the definition/use of specific terms.
   Google Scholar
• Revicki D, Frank L. Pharmacoeconomic evaluation in the real world. PharmacoEconomics 15(5), 423–434 (1999).
   PubMed Web of Science ®Google Scholar
• Payne K, Esmonde-White S. Observation studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Cum Hypertens. Rep. 2,515–524 (2000).
   Google Scholar
• •Study regarding compliance.
   Google Scholar
• Gerth WC. Compliance and persistence with newer antihypertensive agents. Cum Hypertens. Rep. 4,424–433 (2002).
   PubMed Web of Science ®Google Scholar
• •Shows compliance among different classes of antihypertensives.
   Google Scholar
• Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avom J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Arm j Hypertens. 10,697–704 (1997).
   PubMed Web of Science ®Google Scholar
• Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can. J. Public Health 89(5), 16–18 (1998).
   Google Scholar
• Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. In: Health Care Cost, Quality and Outcorms. ISPOR Book of Tirms. International Society for Pharmacoeconomics and Outcomes Research, 22 (2003).
   Google Scholar
• Patel R, Taylor S. Factors affecting medication adherence in hypertensive patients. Ann. Pharmacother. 36,40–45 (2002).
   PubMed Web of Science ®Google Scholar
• Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Cum Hypertens. Rep. 2, 510–514 (2000).
   PubMedGoogle Scholar
• Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Amh. Intern Med. 150(7), 1509–1510 (1990).
   Google Scholar
• Degli Esposti L, Degli Esposti E, Valpiani G et al A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin. Ther. 24(8), 1347–1357, discussion 1346 (2002).
   Google Scholar
• •Measures persistence.
   Google Scholar
• Dasing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press. 7,313–315 (1998).
   PubMedGoogle Scholar
• •Investigates the reasons for noncompliance.
   Google Scholar
• Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 160(1), 31–37 (1999).
   PubMed Web of Science ®Google Scholar
• Jokisalo E, Kumpusalo E, Enlund H, Halonen P, Takala J. Factors related to noncompliance with antihypertensive drug therapy. Hum. Hypertens. 16(8), 577–583 (2002).
   Google Scholar
• Ren XS, Kazis LE, Lee A, Zhang H, Miller DR. Identifying patient and physician characteristics that affect compliance with antihypertensive medications. j Clin. Ther. 27(1), 47–56 (2002).
   Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther. 24(2), 302–316 (2002).
   PubMedGoogle Scholar
• Schmieder RE, Rockstroh JK, Gatzka CD, Ruddel H, Schachinger H. Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of successful withdrawal in a hypertensive community. Cardiology 88(3), 277–284 (1997).
   PubMedGoogle Scholar
• Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med. Care 37(9), 846–857 (1999).
   PubMed Web of Science ®Google Scholar
• Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. IJCP53(1), 37–38 (1999).
   Google Scholar
• BaileyB, Carney S, Gillies A, McColm L, Smith A, Taylor M. Hypertension treatment compliance: what do patients want to know about their medications? Frog. Catrliovasc. NUTS. 12(4), 23–28 (1997).
   Google Scholar
• Kyngas H, Lahdenpera T Compliance of patients with hypertension and associated factors. Adv. Nuts. 29 (4), 832–839 (1999).
   Google Scholar
• Balazovjech I, Hnilica P Jr. Compliance with antihypertensive treatment in consultation rooms for hypertensive patients.j Hum. Hypertens. 7(6), 581–583 (1993).
   Google Scholar
• •Of interest to investigate reasons for noncompliance.
   Google Scholar
• Richardson MA, Simons-Morton B, Annegers JE Effect of perceived barriers on compliance with antihypertensive medication. Health Educ. Q. 20(4), 489–503 (1993).
   Google Scholar
• Morrell RW, Park DC, Kidder DP, Martin M. Adherence to antihypertensive medications across the life span. Gerontologist 37 (5), 609–619 (1997) .
   PubMed Web of Science ®Google Scholar
• Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int.j Canliol. 76(2-3), 157–163 (2000).
   Google Scholar
• •Investigates the reasons for noncompliance.
   Google Scholar
• Choo PW, Rand CS, Inui TS, Lee ML, Canning C, Platt R. A cohort study of possible risk factors for over-reporting of antihypertensive adherence. BMC Carcliovasc. Disonll (2001).
   Google Scholar
• Lee JY, Kusek JVV, Greene PG et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am. Hypertens. 9(8), 719–725 (1996).
   PubMed Web of Science ®Google Scholar
• Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BE Med 323,142–146 (2001).
   PubMedGoogle Scholar
• Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BE Med. j 311,293–295 (1995).
   Google Scholar
• Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avom J. Compliance with antihypertensive therapy among elderly Medicaid enrolees: the roles of age, gender, and race. Am. j Public Health 86(12), 1805–1808 (1996).
   PubMed Web of Science ®Google Scholar
• Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J. Hum. Hypertens. 12(8), 533–537 (1998).
   Google Scholar
• •Measures persistence.
   Google Scholar
• Okano GJ, Rascati K, Wilson J, Remuund D, Grabenstein J, Brbmer D. Patterns of antihypertensive use among patients in the US Department of Defence Database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin. Ther. 19(6), 1433–1445 (1997).
   PubMedGoogle Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther 19(6), 1446–1457 (1997).
   PubMed Web of Science ®Google Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin. Ther. 20(4), 671–681 (1998).
   Google Scholar
• Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CM4J160(1), 41–46 (1999).
   Google Scholar
• •Measures persistence.
   Google Scholar
• Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann. Pharmacother. 36(6), 986–991 (2002).
   Google Scholar
• Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can.j Canliol. 18(6), 649–656 (2002).
   Google Scholar
• Degli Esposti E, Sturani A, Di Martino M et al Long-term persistence with antihypertensive drugs in new patients. J. Hum. Hypertens. 16(6), 439–444 (2002).
   Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J. Hum. Hypertens. 16(8), 569–575 (2002).
   Google Scholar
• •Measures persistence.
   Google Scholar
• Burnier M, Scheneider MP, Chicaro A, et al Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J. Hypertens. 19(2), 335–341 (2001)
   PubMed Web of Science ®Google Scholar
• Saito I, Saruta T Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens. Res. 26(2), 159–162 (2003).
   PubMedGoogle Scholar
• Gregoire JP, Moisan J, Guibert R et al. Determinants of discontinuation of new courses of antihypertensive medications. J. Clin. Epidemiol 55(7), 728–735 (2002).
   Google Scholar
• Detry JM. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Clin. CanJiol. 17(Suppl. III), 11112— 11116 (1994).
   Google Scholar
• Detry JM, Block P, De Backer G, Degaute JR Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur I Clin. Pharmacol 47(6), 477–481 (1995).
   Google Scholar
• Elliott HL, Elawad M, Wilkinson R, Singh SR Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J. Hypertens. 20(2), 333–338 (2002).
   PubMed Web of Science ®Google Scholar
• Mounier-Vehier C, Bemaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am. J. Hypertens. 11,478–486 (1998).
   Google Scholar
• Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once- versus twice-daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. j Cardiol 13(10), 914–920 (1997).
   PubMed Web of Science ®Google Scholar
• Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once-daily- versus twice-daily regimen. Am. j Hypertens. 13(2), 184–190 (2000).
   PubMedGoogle Scholar
• Boissel JP, Meillard O, Perrin-Fayolle E et al Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Eur j Gun. Pharmacol 50(1–2), 63–67 (1996).
   Google Scholar
• Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag. Care 9(9), S2—S6 (2000).
   Google Scholar
• Benson S, Kyle VB, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Arn. I Health-Syst. Pharm. 57(1), 51–54 (2000).
   Google Scholar
• Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. j Hum. Hypertens. 7(5), 515–518 (1993).
   Google Scholar
• Friedman RII, Kazis LE, Jette A et al Telecommunications system for monitoring and counselling patients with hypertension. Impact on medication adherence and blood pressure control. Amj Hypertens. 9(4 Pt 1), 285–292 (1996).
   Google Scholar
• Patton K, Meyers J, Lewis BE. Enhancement of compliance among patients with hypertension. Am. j Manag Care 3(11), 1693–1698 (1997).
   Google Scholar
• Collins L, Ivey AM. The relationship of patient education and hypertension treatment compliance. j Am Acad. Nurse Pract. 11(8), 331–334 (1999).
   Google Scholar
• Applegate BW, Ames SC, Mehan DJ Jr, McKnight GT, Jones GN, Brantley PJ. Maximizing medication adherence in low-income hypertensives: a pilot study. J. LA State Med. Soc. 152,349–356 (2000).
   PubMedGoogle Scholar
• Enlund H, Jokisalo E, Wallenius S, Korhonen M. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm. World Sc]. 23(2), 60–64 (2001).
   PubMedGoogle Scholar
• Cramer, JA, Ouellette, VL, Mattson, RII. The effect of microelectronic observation on compliance. 43i/Epsia 31,617–618 (1990).
   Google Scholar
• Rudd P Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev 25,230–240 (1994).
   Google Scholar
• Park DC. Applied cognitive aging research. In: The Handbook of Aging and Cognition. Craik FIM, Salthouse TA (Eds). Laurence Erlbaum, NJ, USA, 449–493 (1992)
   Google Scholar
• Park DC. Self-regulation and control of rheumatic disorders. Int. Rev Health P9rhol. 3,189-197 (1994).
   Google Scholar
• Park DC, Jones TR. Medication adherence and aging. In: Handbook of Human Factors and the Holder Adult. Fish AD, Rogers WA (Eds). Laurence Erlbaum, NJ, USA 369–390, (1996)
   Google Scholar
• Janz NK, Becker MR. The health belief model: a decade later. Heath Educ. Q 11, 1–47 (1984).
   PubMedGoogle Scholar
• Sole240reSAnita. USA: Compliance Nel Mirino. The Boston Consulting Group. 4 (11), 3–9 (2004).
   Google Scholar
• Home R, Clatworthy J, Polmear A, Weinman J. Anglo—Scandinavian Cardiac Outcomes Trial. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life?' Hum. Hypertens. 15 (Suppl. 1), S65—S68 (2001).
   Google Scholar
• Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J. Nerv Mental Dis. 187,52–54 (1999).
   Web of Science ®Google Scholar
• •Shows the use of standardized and effective programs to improve compliance and the use of placebo in studies measuring compliance.
   Google Scholar
• Cramer JA, Rosenheck R, Kirk G, Krol W, Krystal JH and the VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6, 566–573 (2003).
   Google Scholar
• •Used for the standardized and effective programs to improve compliance.
   Google Scholar
• Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy21(8), 940–953 (2001).
   PubMedGoogle Scholar
• Salas M, Tnt Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin. Pharmacol Ther. 70(6), 561–566 (2001).
   PubMed Web of Science ®Google Scholar
• Mallion JM, Dutrey-Dupagne C, Vaur L et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild-to-moderate hypertension. J. Hypertens. 14(1), 137–144 (1996).
   PubMedGoogle Scholar
• Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacodynamic assessment of the impact of antihypertensive nonadherence on blood pressure control. Pharmacoepidemiol Drug Sal 9(7), 557–563 (2000).
   PubMedGoogle Scholar
• Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J. Hum. Hypertens. 16(11), 779–787 (2002).
   Google Scholar